A deep learning derived prostate zonal volume-based biomarker from T2-weighted MRI to distinguish between prostate cancer and benign prostatic hyperplasia.

BACKGROUND

Benign prostatic hyperplasia (BPH) and prostate cancer (PCa) share overlapping characteristics on magnetic resonance imaging (MRI), confounding the diagnosis and detection of PCa. There is thus a clinical need to accurately differentiate BPH-Only from BPH-PCa to prevent overdiagnosis and unnecessary biopsies. Although BPH and PCa may share overlapping features, they are distinct clinical entities. Previous evidence suggests that prostate peripheral zone (PZ) and transition zone (TZ) volumes on MRI are differentially associated in patients with BPH-PCa versus those with BPH-Only.

PURPOSE

To develop and validate the ratio of machine learning derived PZ and TZ volumes on T2-weighted (T2W) MRI as an imaging biomarker to distinguish BPH-PCa and BPH-Only.

METHODS

In this single-center, retrospective study, we identified N = 199 patients (106 BPH-Only and 93 with both BPH-PCa) who underwent a three Tesla multi-parametric MRI before systematic biopsy. A radiologist and a urologist jointly annotated PZ and TZ regions of interest on T2W, involving all 199 cases. We presented and trained a 3D conditional generative adversarial network (cGAN)-based prostate zone volume segmentation model (ProZonaNet) to segment 3D prostate TZ, PZ volumes on T2W MRI. We used 139 cases (with 7× data augmentation, yielding 973 training volumes) and an independent test set of 60 cases to train and evaluate ProZonaNet. ProZonaNet was optimized in terms of dice similarity coefficient (DSC). We then computed prostate zonal volume ratio (pZVR = TZ/PZ) from both ProZonaNet segmentations and ground-truth annotations on all 199 cases, evaluating agreement using Concordance Correlation Coefficient (CCC). The pZVR biomarker was assessed for its ability to distinguish BPH-PCa from BPH-Only. Univariate and multivariate analyses were performed to evaluate the independent effect of pZVR over clinical parameters.

RESULTS

ProZonaNet achieved a mean mDICE of 92.5% on the independent test set (N = 60), outperforming state-of-the-art 3D segmentation models. The computed pZVR showed high agreement with ground-truth annotations, with CCC values of 0.960 for BPH-Only and 0.930 for BPH-PCa cases. The pZVR computed using ProZonaNet, along with two other clinical parameters, including age and prostate-specific antigen, improved the AUC from 0.758 to 0.927 in distinguishing between BPH-Only and BPH-PCa. At the same time, on a subset of low-grade prostate cancer cases (106 BPH-Only and 23 BPH-PCa with Gleason Score = 3+3), the integrated pZVR model improved the AUC from 0.750 to 0.910 in distinguishing between patients with BPH-Only versus BPH-PCa. On both univariate and multivariate analyses, pZVR demonstrated significant discrimination between patients with BPH-Only versus BPH-PCa.

CONCLUSIONS

We demonstrated that the prostate zonal volume ratio computed with our ProZonaNet can be used to differentiate benign prostatic hyperplasia from prostate cancer on MRI. These results demonstrate the feasibility of non-invasive diagnosis of BPH-PCa, potentially aiding in the ability to distinguish PCa from benign cancer confounders such as BPH-Only.